Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10347965 | 0.82 | TDP1 (0.39) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL9837020 | 0.82 | CYP3A4 (0.46) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL7931545 | 0.79 | TDP1 (0.45) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL28565939 | 0.79 | TDP1 (0.41) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL6594425 | 0.79 | TRPV4 (0.47) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL7675744 | 0.79 | KIF11 (0.32) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL26726215 | 0.78 | CYP3A4 (0.50) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL31401921 | 0.76 | CYP3A4 (0.35) | CYP3A4TRPA1TDP1ALDH1A1HPGD | |
| SCHEMBL8485253 | 0.76 | TDP1 (0.43) | CYP3A4TDP1ALDH1A1HPGDMAPK1 | |
| SCHEMBL1399737 | 0.75 | ABCB11 (0.34) | CYP3A4TDP1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104418773-A | Synthetic method of 2,4,5-trifluoro-benzene isocyanate and intermediate thereof | KNOWSHINE SHANGHAI PHARMACHEMICALS INC | 2015-03-18 | — | — | CN | claimed |
| CN-107849816-B | Method for treating paperboard and paper media and related treated paperboard and paper media | 巴斯夫欧洲公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-108753220-B | High-temperature-resistant and solvent-resistant phenolic resin film | 长春峰泰汽车胶业有限公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-106575789-B | Electrolyte formulation | 野猫技术开发公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-106232667-B | Polyiso-ureas | 巴斯夫欧洲公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-3132487-B1 | ELECTROLYTE FORMULATIONS | Wildcat discovery technologies inc (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180298557-A1 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED TREATED PAPERBOARDS AND PAPER MEDIA | BASF CORPORATION | 2018-10-18 | — | — | US | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-9982083-B2 | Polyiso-urea | BASF SE (DE) | 2018-05-29 | — | — | US | disclosed |
| EP-3298194-A2 | METHODS FOR TREATING PAPERBOARDS AND PAPER MEDIA, AND ASSOCIATED PAPERBOARDS AND PAPER MEDIA | BASF SE (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
| US-20110091768-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-2190054-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-05-26 | — | — | EP | disclosed |
| EP-2111443-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | The Procter and Gamble Company (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200363-A1 | Perfumes, brighteners, insect repellants, flavors, vitamins, fabric softeners, skin care agents; increasing potency, reducing cost | PROECTER & GAMBLE COMPANY, THE | 2008-08-21 | — | — | US | disclosed |
| WO-2008100601-A2 | BENEFIT AGENT DELIVERY COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | CYP3A4 2032/4885TRPA1 2026/4885TDP1 4723/4885 |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | CYP3A4 1000/4885TRPA1 2525/4885TDP1 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.